Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases

Acta Oncologica

Volumn 52, Issue 1, 2013, Pages 175-178

  Martens, Jennifer ^a   Venuturumilli, Padmaja ^a   Corbets, Lindsey ^b   Bestul, Daniel ^a  

^a BEAUMONT HOSPITAL   (United States)

^b Captain James A Lovell Federal Health Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; LAPATINIB; METHOTREXATE; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOSE; PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; BLADDER CATHETERIZATION; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CAUDA EQUINA; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; CRANIOTOMY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HER 2 POSITIVE BREAST CANCER; HOSPICE CARE; HUMAN; LEPTOMENINGEAL METASTASIS; LETTER; LIVER METASTASIS; MASTECTOMY; NERVE ROOT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PRIORITY JOURNAL; QUALITY OF LIFE; REOPERATION; SPINAL CORD DORSAL HORN; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SEEDING; UNSTEADINESS; URINE RETENTION; BREAST METASTASIS; CANCER STAGING; CEREBROSPINAL FLUID CYTOLOGY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FRONTAL LOBE; GLUCOSE BLOOD LEVEL; INTRADUCTAL CARCINOMA; LIMB WEAKNESS; MENINGEAL METASTASIS; NEUROIMAGING; OMMAYA RESERVOIR; PHYSIOTHERAPY; PROTEIN BLOOD LEVEL; STEREOTACTIC RADIOSURGERY; TUMOR RECURRENCE; UNSTEADY GAIT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INJECTIONS, SPINAL; MAGNETIC RESONANCE IMAGING; MENINGEAL CARCINOMATOSIS; METHOTREXATE; RECEPTOR, ERBB-2;

EID: 84871403219     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.689857     Document Type: Letter

References (14)

1. Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches. Oncologist 2011;16:1175-88.
2. Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, et al. Application of intrathecal trastuzumab (HerceptinTM) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006;15:1373-7.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. v.1.2012. Accessed 2012 Mar 7. Available from: http://www. nccn.org/professionals/physician-gls/f-guidelines. asp#site.
4. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402.
5. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: A randomized study. Eur J Cancer 2004;40:2726-33. (Pubitemid 39574724)
6. Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis - the role of multimodality treatment. J Neurooncol 2007;84:57-62. (Pubitemid 47103444)
7. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001;2:235 (letter). (Pubitemid 33085772)
8. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006;7:778-80. (Pubitemid 44283672)
9. Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Hermann KA, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2- overexpressing metastatic breast cancer: A case report. Anticancer Drugs 2008;19:832-6.
10. Shojima K, Suzuki E, Saito K, Sekine D, Kitagawa T, Aruga S, et al. Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol 2008;26(Suppl);1138 (abstract).
11. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008;19:1978-80 (letter).
12. Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, Aristei C, et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009;63:1157-9.
13. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009;20:792-5 (letter).
14. Allison DL, Glantz M, Werner TL, Kirkegaard SL, Murdock K, Jensen R. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. J Clin Oncol 2009;27(Suppl):2066 (abstract).